142 related articles for article (PubMed ID: 22483234)
61. Glypican-3 mRNA expression level in Wilms tumor: correlation with histological type, stage, and outcome.
Wari MN; Vallonthaiel AG; Ahmed A; Saxena D; Iyer VK; Mathur SR; Agarwala S; Bakhshi S; Srinivas V; Chattopadhyaya P; Sharma A; Gupta SD; Dinda A
Pediatr Surg Int; 2017 Jun; 33(6):695-703. PubMed ID: 28432433
[TBL] [Abstract][Full Text] [Related]
62. p53 accumulation in favorable-histology Wilms tumor is associated with angiogenesis and clinically aggressive disease.
Huang J; Soffer SZ; Kim ES; Yokoi A; Moore JT; McCrudden KW; Manley C; Middlesworth W; O'Toole K; Stolar C; Yamashiro DJ; Kandel JJ
J Pediatr Surg; 2002 Mar; 37(3):523-7. PubMed ID: 11877681
[TBL] [Abstract][Full Text] [Related]
63. Chromosome analyses of 16 cases of Wilms tumor: different pattern in unfavorable histology.
Peres EM; Savasan S; Cushing B; Abella S; Mohamed AN
Cancer Genet Cytogenet; 2004 Jan; 148(1):66-70. PubMed ID: 14697643
[TBL] [Abstract][Full Text] [Related]
64. Immunohistochemical detection of p53 protein expression as a prognostic indicator in Wilms tumor.
Sredni ST; de Camargo B; Lopes LF; Teixeira R; Simpson A
Med Pediatr Oncol; 2001 Nov; 37(5):455-8. PubMed ID: 11745874
[TBL] [Abstract][Full Text] [Related]
65.
Liu P; Zhuo Z; Li W; Cheng J; Zhou H; He J; Zhang J; Wang J
Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30610160
[TBL] [Abstract][Full Text] [Related]
66. Multiple mechanisms of MYCN dysregulation in Wilms tumour.
Williams RD; Chagtai T; Alcaide-German M; Apps J; Wegert J; Popov S; Vujanic G; van Tinteren H; van den Heuvel-Eibrink MM; Kool M; de Kraker J; Gisselsson D; Graf N; Gessler M; Pritchard-Jones K
Oncotarget; 2015 Mar; 6(9):7232-43. PubMed ID: 25749049
[TBL] [Abstract][Full Text] [Related]
67. The association of miR34b/c and TP53 gene polymorphisms with Wilms tumor risk in Chinese children.
Wang J; Lou S; Huang X; Mo Y; Wang Z; Zhu J; Tian X; Shi J; Zhou H; He J; Ruan J
Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 32083300
[TBL] [Abstract][Full Text] [Related]
68. A Murine Model of K-RAS and β-Catenin Induced Renal Tumors Expresses High Levels of E2F1 and Resembles Human Wilms Tumor.
Yi Y; Polosukhina D; Love HD; Hembd A; Pickup M; Moses HL; Lovvorn HN; Zent R; Clark PE
J Urol; 2015 Dec; 194(6):1762-70. PubMed ID: 25934441
[TBL] [Abstract][Full Text] [Related]
69. Loss of heterozygosity and SOSTDC1 in adult and pediatric renal tumors.
Blish KR; Clausen KA; Hawkins GA; Garvin AJ; Willingham MC; Turner JC; Torti FM; Torti SV
J Exp Clin Cancer Res; 2010 Nov; 29(1):147. PubMed ID: 21080955
[TBL] [Abstract][Full Text] [Related]
70. Expression of YY1 in Wilms tumors with favorable histology is a risk factor for adverse outcomes.
Zapata-Tarres M; Juarez-Villegas LE; Maldonado-Valenzuela A; Baay-Guzman GJ; Lopez-Perez TV; Cabrera-Muñoz L; Sadowinski-Pine S; Huerta-Yepez S
Future Oncol; 2019 Apr; 15(11):1231-1241. PubMed ID: 30810052
[TBL] [Abstract][Full Text] [Related]
71. Peptide spectra in Wilms tumor that associate with adverse outcomes.
Murphy AJ; Pierce J; Seeley EH; Sullivan LM; Ruchelli ED; Nance ML; Caprioli RM; Lovvorn HN
J Surg Res; 2015 Jun; 196(2):332-8. PubMed ID: 25868780
[TBL] [Abstract][Full Text] [Related]
72. The epithelial mesenchymal transition process in wilms tumor: a study based on a xenograft model.
Giner F; Machado I; Noguera R; Villamon E; Pellin A; Calabuig-Fariñas S; Peydro-Olaya A; Navarro S; Llombart-Bosch A
Appl Immunohistochem Mol Morphol; 2011 Jul; 19(4):369-75. PubMed ID: 21285869
[TBL] [Abstract][Full Text] [Related]
73. B7-H1 expression in Wilms tumor: correlation with tumor biology and disease recurrence.
Routh JC; Ashley RA; Sebo TJ; Lohse CM; Husmann DA; Kramer SA; Kwon ED
J Urol; 2008 May; 179(5):1954-9; discussion 1959-60. PubMed ID: 18355839
[TBL] [Abstract][Full Text] [Related]
74. Age distributions, birth weights, nephrogenic rests, and heterogeneity in the pathogenesis of Wilms tumor.
Breslow NE; Beckwith JB; Perlman EJ; Reeve AE
Pediatr Blood Cancer; 2006 Sep; 47(3):260-7. PubMed ID: 16700047
[TBL] [Abstract][Full Text] [Related]
75. A Gradual Transition Toward Anaplasia in Wilms Tumor Through Tolerance to Genetic Damage.
Uno K; Rastegar B; Jansson C; Durand G; Valind A; Chattopadhyay S; Bertolotti A; Ciceri S; Spreafico F; Collini P; Perotti D; Mengelbier LH; Gisselsson D
Mod Pathol; 2024 Jan; 37(1):100382. PubMed ID: 37951357
[TBL] [Abstract][Full Text] [Related]
76. Immunohistochemical expression of P53 protein in nephroblastoma: a predictor of unfavorable prognosis.
Morgan ED; Yahaya JJ; Ngaiza AI; Othieno E; Livex OA
J Egypt Natl Canc Inst; 2023 Jul; 35(1):23. PubMed ID: 37518096
[TBL] [Abstract][Full Text] [Related]
77. Association Between TP53 Mutation and Prognosis in Wilms Tumor: A Meta-Analysis.
Lizhi L; Rongdong H; Shaohua H; Yingquan K; Huihuang X; Shan L; Kunbin T; Di X
Fetal Pediatr Pathol; 2021 Dec; 40(6):653-662. PubMed ID: 32066305
[No Abstract] [Full Text] [Related]
78. Using Elevated Cholesterol Synthesis as a Prognostic Marker in Wilms' Tumor: A Bioinformatic Analysis.
He Y; Cui X; Lin Y; Wang Y; Wu D; Fang Y
Biomed Res Int; 2021; 2021():8826286. PubMed ID: 33628817
[TBL] [Abstract][Full Text] [Related]
79. A unique subset of low-risk Wilms tumors is characterized by loss of function of TRIM28 (KAP1), a gene critical in early renal development: A Children's Oncology Group study.
Armstrong AE; Gadd S; Huff V; Gerhard DS; Dome JS; Perlman EJ
PLoS One; 2018; 13(12):e0208936. PubMed ID: 30543698
[TBL] [Abstract][Full Text] [Related]
80. Glypican-3 expression in Wilms tumor and hepatoblastoma.
Toretsky JA; Zitomersky NL; Eskenazi AE; Voigt RW; Strauch ED; Sun CC; Huber R; Meltzer SJ; Schlessinger D
J Pediatr Hematol Oncol; 2001 Nov; 23(8):496-9. PubMed ID: 11878776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
